“The Board of directors of Oriflame Holding Limited, the Company and its advisers are proactively exploring options to address its capital structure and are evaluating potential recapitalisation opportunities.
In connection with such efforts, the Company is in constructive and active discussions with a group of investors who are majority holders of the Company’s Euro and USD senior secured notes.
No assurance can be given with respect to the outcome of any such negotiations.”
Three months ended 30 September 2024
Euro sales decreased by 19% to €130.8m (€161.7m) and local currency sales decreased by 16%.
The adjusted EBITDA amounted to €5.4m (€4.1m) and the adjusted EBITDA margin was 4.2% (2.5%). The currency impact on the adjusted EBITDA was 170 bps negative.
The adjusted operating profit was €0.2m (€-1.7m) and the adjusted operating margin was 0.2% (-1.1%).
The adjusted net profit was €6.9m (€-54.2m).
The adjusted cash flow from operating activities was €-10.9m (€-6.9m) and adjusted cash flow before financing activities was €-13.0m (€-13.9m).
Additional non-recurring costs amounting to €1.5m (€20.3m) were recorded during the quarter and excluded from the operating profit (adjusted operating profit).
Oriflame Sales 2018 – 2023
Nine months ended 30 September 2024
Euro sales decreased by 21% to €435.5m (€551.9m) and local currency sales decreased by 17%.
The adjusted